GBS GLUCOSE BIOSENSOR SYS

GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

GBS Inc. to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on August 31

Company to Host Conference Call & Webcast at 4:30 p.m. ET

NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the fourth quarter and full year ended June 30, 2022, shortly after the NASDAQ market close on Wednesday, August 31. Management will then host a conference call and webcast at 4:30 p.m. ET.

Title:GBS Inc. Fourth Quarter and Full Year 2022 Financial Results

Conference Call & Webcast
Date:Wednesday, August 31, 2022
Time:4:30 p.m. ET
Conference Call Details:Toll-Free: 877-407-3982

International: 201-493-6780

Conference ID: 13731215
 
The conference call will be webcast live from the Company’s website and will be available via the following links:

 
Webcast:



  
The webcast should be accessed 15 minutes prior to the conference call start time.

A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the Company’s website.

About GBS Inc.:

GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help people living with diabetes. For more information, please visit .        

Company Contact:

Alex Arzeno – Vice President of IR & Communications

GBS, Inc.

Investor Contact:

Tim McCarthy – Managing Director

LifeSci Advisors, LLC



EN
29/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GLUCOSE BIOSENSOR SYS

 PRESS RELEASE

Intelligent Bio Solutions Announces Strategic Partnership with Vlepis,...

Intelligent Bio Solutions Announces Strategic Partnership with Vlepis, Provider of Advanced Sensing and Wearable Patch Technologies, to Drive Innovation in Non-Invasive Screening and Consumer Health Monitoring Companies to leverage and collaborate on research and development, distribution, and regulatory expertise to accelerate global adoption of intelligent testing technologies Alliance positions INBS to enter the fast-growing consumer health market, broadening revenue opportunities beyond commercial screening NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (...

 PRESS RELEASE

Intelligent Bio Solutions Inc. Announces Reverse Stock Split

Intelligent Bio Solutions Inc. Announces Reverse Stock Split NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it will effect a 1-for-10 reverse split of its common stock, that will become effective at 11:59 pm (Eastern Time) on December 15, 2025. Trading of the Company's common stock on The Nasdaq Capital Market (“Nasdaq”) will continue, on a split-adjusted basis, with the opening of the ma...

 PRESS RELEASE

Intelligent Bio Solutions to Participate in Noble Capital Markets’ 21s...

Intelligent Bio Solutions to Participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference on December 2-3, 2025 NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that its management team will participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference, taking place over December 2-3, 2025, in Boca Raton, Florida. Conference DetailsDate:  December 2–3, 2025Location:  Flo...

 PRESS RELEASE

Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial ...

Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth Record quarterly revenue of $1.11 million, an increase of 32% sequentially and 28% year-over-year, driven by consumable cartridge sales and customer base expansion Gross profit margins increased 690 basis points year-over-year to 46.6%, reflecting improved operational efficiency and greater revenue percentage from higher margin cartridge sales NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Co...

 PRESS RELEASE

Intelligent Bio Solutions Expects to Report Record Fiscal First Quarte...

Intelligent Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially and 28% Year-Over-Year Company Achieves Third Consecutive Quarter of Revenue Growth Revenue Increase of Approximately 32% Sequentially and 28% Year-Over-Year Driven by New Customer Accounts and Strong Cartridge and Reader Sales Cartridge and Reader Revenue Up Approximately 43% and 23% Year-Over-Year Respectively NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medica...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch